Tumor and organ uptake of 64Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies
- 1 November 2015
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (11) , 880-886
Abstract
No abstract availableKeywords
Funding Information
- Clinical Center, NIH
This publication has 29 references indexed in Scilit:
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical DevelopmentMolecular Cancer Therapeutics, 2012
- PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PETTumor Biology, 2012
- Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTAPLOS ONE, 2011
- Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibodyNuclear Medicine and Biology, 2011
- Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing CancersClinical Cancer Research, 2010
- A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins UptakeCancer Research, 2010
- Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-TrastuzumabPLOS ONE, 2010
- Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 StandardsJournal of Nuclear Medicine, 2009
- Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumorsProceedings of the National Academy of Sciences, 2007
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976